

Deel VII. Referenties

- (1) The AGREE Collaboration. Appraisal of Guidelines Research & Evaluation. Instrument voor beoordeling van richtlijnen. www.agreecollaboration.org/pdf/nl.pdf [2001 [cited 2008 Nov. 28];
- (2) The ADAPTE Collaboration. ADAPTE manual. ADAPTE Resource toolkit. www.adapte.org 2009.
- (3) Speelman J. Ziekte van Parkinson. Nationaal Kompas Volksgezondheid [2007 [cited 2008 Aug.]; Available from: URL:www.nationaalkompas.nl
- (4) de Lau LM, Breteler MM. Epidemiology of Parkinson's disease 59. *Lancet Neurol* 2006; 5(6):525-535.
- (5) de Rijk MC, Tzourio C, Breteler MM, Dartigues JF, Amaducci L, Lopez-Pousa S et al. Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson's disease. *J Neurol Neurosurg Psychiatry* 1997; 62(1):10-15.
- (6) de Lau LM, Giesbergen PC, de Rijk MC, Hofman A, Koudstaal PJ, Breteler MM. Incidence of parkinsonism and Parkinson disease in a general population: the Rotterdam Study 111. *Neurology* 2004; 63(7):1240-1244.
- (7) de Lau LM, Schipper CM, Hofman A, Koudstaal PJ, Breteler MM. Prognosis of Parkinson disease: risk of dementia and mortality: the Rotterdam Study 82. *Arch Neurol* 2005; 62(8):1265-1269.
- (8) NICE. Parkinson's disease. Diagnosis and management in primary and secondary care (NICE clinical guideline 35). London, UK: National collaborating centre for chronic conditions; 2006.
- (9) Findley LJ. The economic impact of Parkinson's disease. *Parkinsonism Relat Disord* 2007; 13 Suppl:S8-S12.
- (10) Findley L, Aujla M, Bain PG, Baker M, Beech C, Bowman C et al. Direct economic impact of Parkinson's disease: a research survey in the United Kingdom. *Mov Disord* 2003; 18(10):1139-1145.
- (11) Keranen T, Kaakkola S, Sotaniemi K, Laulumaa V, Haapaniemi T, Jolma T et al. Economic burden and quality of life impairment increase with severity of PD. *Parkinsonism Relat Disord* 2003; 9(3):163-168.
- (12) Sato K, Hatano T, Yamashiro K, Kagohashi M, Nishioka K, Izawa N et al. Prognosis of Parkinson's disease: time to stage III, IV, V, and to motor fluctuations. *Mov Disord* 2006; 21(9):1384-1395.
- (13) Munneke M, Keus S, Nijkrake M, Kwakkel G, Berendse H, Roos R et al. Efficiency of evidence-based physiotherapy for Parkinson's disease: The ParkinsonNet trial. *Mov Disord* 2007; 23((Suppl.1)):S220.
- (14) Hjelmgren J, Ghatnekar O, Reimer J, Grabowski M, Lindvall O, Persson U et al. Estimating the value of novel interventions for Parkinson's disease: an early decision-making model with application to dopamine cell replacement. *Parkinsonism Relat Disord* 2006; 12(7):443-452.
- (15) Drummond MF, O'Brien B, Stoddart GL, Torrance GW. *Methods for the Economic Evaluation of Health Care Programmes*. second edition ed. Oxford: Oxford University Press; 1997.
- (16) Gage H, Storey L. Rehabilitation for Parkinson's disease: a systematic review of available evidence. *Clin Rehabil* 2004; 18(5):463-482.
- (17) Poos MJJC, Smit JM, Groen J, Kommer GJ, Slobbe LCJ. Kosten van Ziekten in Nederland 2005. RIVM [2008 Available from: URL:www.kostenvanziekten.nl
- (18) Hagell P, Nordling S, Reimer J, Grabowski M, Persson U. Resource use and costs in a Swedish cohort of patients with Parkinson's disease. *Mov Disord* 2002; 17(6):1213-1220.
- (19) Alves G, Larsen JP, Emre M, Wentzel-Larsen T, Aarsland D. Changes in motor subtype and risk for incident dementia in Parkinson's disease. *Mov Disord* 2006; 21(8):1123-1130.
- (20) Daniel SE, Lees AJ. *Parkinson's Disease Society Brain Bank*, London: overview and research. *J Neural Transm Suppl* 1993; 39:165-172.
- (21) Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. *J Neurol Neurosurg Psychiatry* 1992; 55(3):181-184.
- (22) Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. *Brain* 2002; 125(Pt 4):861-870.

- (23) Rajput AH, Rozdilsky B, Rajput A. Accuracy of clinical diagnosis in parkinsonism--a prospective study. *Can J Neurol Sci* 1991; 18(3):275-278.
- (24) Jankovic J, Rajput AH, McDermott MP, Perl DP. The evolution of diagnosis in early Parkinson disease. Parkinson Study Group. *Arch Neurol* 2000; 57(3):369-372.
- (25) Lees AJ, Katzenschlager R, Head J, Ben-Shlomo Y. Ten-year follow-up of three different initial treatments in de-novo PD: a randomized trial. *Neurology* 2001; 57(9):1687-1694.
- (26) Meara J, Bhowmick BK, Hobson P. Accuracy of diagnosis in patients with presumed Parkinson's disease. *Age Ageing* 1999; 28(2):99-102.
- (27) Schrag A, Ben-Shlomo Y, Quinn N. How valid is the clinical diagnosis of Parkinson's disease in the community? *J Neurol Neurosurg Psychiatry* 2002; 73(5):529-534.
- (28) Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. *Arch Neurol* 1999; 56(1):33-39.
- (29) A multicenter assessment of dopamine transporter imaging with DOPASCAN/SPECT in parkinsonism. Parkinson Study Group. *Neurology* 2000; 55(10):1540-1547.
- (30) Acton PD, Mozley PD, Kung HF. Logistic discriminant parametric mapping: a novel method for the pixel-based differential diagnosis of Parkinson's disease. *Eur J Nucl Med* 1999; 26(11):1413-1423.
- (31) Asenbaum S, Pirker W, Angelberger P, Bencsits G, Pruckmayer M, Brucke T. [123I]beta-CIT and SPECT in essential tremor and Parkinson's disease. *J Neural Transm* 1998; 105(10-12):1213-1228.
- (32) Benamer HT, Oertel WH, Patterson J, Hadley DM, Pogarell O, Hoffken H et al. Prospective study of presynaptic dopaminergic imaging in patients with mild parkinsonism and tremor disorders: part 1. Baseline and 3-month observations. *Mov Disord* 2003; 18(9):977-984.
- (33) Benamer TS, Patterson J, Grosset DG, Booij J, de BK, van RE et al. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. *Mov Disord* 2000; 15(3):503-510.
- (34) Booij J, Speelman JD, Horstink MW, Wolters EC. The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism. *Eur J Nucl Med* 2001; 28(3):266-272.
- (35) Catafau AM, Tolosa E. Impact of dopamine transporter SPECT using 123I-loflupane on diagnosis and management of patients with clinically uncertain Parkinsonian syndromes. *Mov Disord* 2004; 19(10):1175-1182.
- (36) Chou KL, Hurtig HI, Stern MB, Colcher A, Ravina B, Newberg A et al. Diagnostic accuracy of [99mTc]TRODAT-1 SPECT imaging in early Parkinson's disease. *Parkinsonism Relat Disord* 2004; 10(6):375-379.
- (37) Huang WS, Lee MS, Lin JC, Chen CY, Yang YW, Lin SZ et al. Usefulness of brain 99mTc-TRODAT-1 SPET for the evaluation of Parkinson's disease. *Eur J Nucl Med Mol Imaging* 2004; 31(2):155-161.
- (38) Jennings DL, Seibyl JP, Oakes D, Eberly S, Murphy J, Marek K. (123I) beta-CIT and single-photon emission computed tomographic imaging vs clinical evaluation in Parkinsonian syndrome: unmasking an early diagnosis. *Arch Neurol* 2004; 61(8):1224-1229.
- (39) Lokkegaard A, Werdelin LM, Friberg L. Clinical impact of diagnostic SPET investigations with a dopamine re-uptake ligand. *Eur J Nucl Med Mol Imaging* 2002; 29(12):1623-1629.
- (40) Popperl G, Radau P, Linke R, Hahn K, Tatsch K. Diagnostic performance of a 3-D automated quantification method of dopamine D2 receptor SPECT studies in the differential diagnosis of parkinsonism. *Nucl Med Commun* 2005; 26(1):39-43.
- (41) Prunier C, Tranquart F, Cottier JP, Giraudeau B, Chalon S, Guilloteau D et al. Quantitative analysis of striatal dopamine D2 receptors with 123 I-iodolisuride SPECT in degenerative extrapyramidal diseases. *Nucl Med Commun* 2001; 22(11):1207-1214.
- (42) Van LK, De CL, Dom R, Van den EJ, Vanbilloen H, Cleynhens J et al. Dopamine transporter SPECT using fast kinetic ligands: 123I-FP-beta-CIT versus 99mTc-TRODAT-1. *Eur J Nucl Med Mol Imaging* 2004; 31(8):1119-1127.
- (43) Varrone A, Marek KL, Jennings D, Innis RB, Seibyl JP. [(123I)]beta-CIT SPECT imaging demonstrates reduced density of striatal dopamine transporters in Parkinson's disease and multiple system atrophy. *Mov Disord* 2001; 16(6):1023-1032.
- (44) Weng YH, Yen TC, Chen MC, Kao PF, Tzen KY, Chen RS et al. Sensitivity and specificity of 99mTc-TRODAT-1 SPECT imaging in differentiating patients with idiopathic Parkinson's disease from healthy subjects. *J Nucl Med* 2004; 45(3):393-401.

- (45) Doepp F, Plotkin M, Siegel L, Kivi A, Gruber D, Lobsien E et al. Brain parenchyma sonography and 123I-FP-CIT SPECT in Parkinson's disease and essential tremor. *Mov Disord* 2008; 23(3):405-410.
- (46) Marshall VL, Patterson J, Hadley DM, Grosset KA, Grosset DG. Two-year follow-up in 150 consecutive cases with normal dopamine transporter imaging. *Nucl Med Commun* 2006; 27(12):933-937.
- (47) Bhattacharya K, Saadia D, Eisenkraft B, Yahr M, Olanow W, Drayer B et al. Brain magnetic resonance imaging in multiple-system atrophy and Parkinson disease: a diagnostic algorithm. *Arch Neurol* 2002; 59(5):835-842.
- (48) Burn DJ, Sawle GV, Brooks DJ. Differential diagnosis of Parkinson's disease, multiple system atrophy, and Steele-Richardson-Olszewski syndrome: discriminant analysis of striatal 18F-dopa PET data. *J Neurol Neurosurg Psychiatry* 1994; 57(3):278-284.
- (49) Cercy SP, Bylsma FW. Lewy bodies and progressive dementia: a critical review and meta-analysis. *J Int Neuropsychol Soc* 1997; 3(2):179-194.
- (50) Juh R, Kim J, Moon D, Choe B, Suh T. Different metabolic patterns analysis of Parkinsonism on the 18F-FDG PET. *Eur J Radiol* 2004; 51(3):223-233.
- (51) Schocke MF, Seppi K, Esterhammer R, Kremser C, Jaschke W, Poewe W et al. Diffusion-weighted MRI differentiates the Parkinson variant of multiple system atrophy from PD. *Neurology* 2002; 58(4):575-580.
- (52) Schreckenberger M, Hagele S, Siessmeier T, Buchholz HG, rmbrust-Henrich H, Rosch F et al. The dopamine D2 receptor ligand 18F-desmethoxyfallypride: an appropriate fluorinated PET tracer for the differential diagnosis of parkinsonism. *Eur J Nucl Med Mol Imaging* 2004; 31(8):1128-1135.
- (53) Paviour DC, Price SL, Stevens JM, Lees AJ, Fox NC. Quantitative MRI measurement of superior cerebellar peduncle in progressive supranuclear palsy. *Neurology* 2005; 64(4):675-679.
- (54) Price S, Paviour D, Scahill R, Stevens J, Rossor M, Lees A et al. Voxel-based morphometry detects patterns of atrophy that help differentiate progressive supranuclear palsy and Parkinson's disease. *Neuroimage* 2004; 23(2):663-669.
- (55) Righini A, Antonini A, Ferrarini M, de NR, Canesi M, Triulzi F et al. Thin section MR study of the basal ganglia in the differential diagnosis between striatonigral degeneration and Parkinson disease. *J Comput Assist Tomogr* 2002; 26(2):266-271.
- (56) Righini A, Antonini A, de NR, Bianchini E, Meucci N, Sacilotto G et al. MR imaging of the superior profile of the midbrain: differential diagnosis between progressive supranuclear palsy and Parkinson disease. *AJNR Am J Neuroradiol* 2004; 25(6):927-932.
- (57) Seppi K, Schocke MF, Esterhammer R, Kremser C, Brenneis C, Mueller J et al. Diffusion-weighted imaging discriminates progressive supranuclear palsy from PD, but not from the parkinson variant of multiple system atrophy. *Neurology* 2003; 60(6):922-927.
- (58) Yekhlief F, Ballan G, Macia F, Delmer O, Sourgen C, Tison F. Routine MRI for the differential diagnosis of Parkinson's disease, MSA, PSP, and CBD. *J Neural Transm* 2003; 110(2):151-169.
- (59) Clarke CE, Davies P. Systematic review of acute levodopa and apomorphine challenge tests in the diagnosis of idiopathic Parkinson's disease. *J Neurol Neurosurg Psychiatry* 2000; 69(5):590-594.
- (60) Albanese A, Bonuccelli U, Brefel C, Chaudhuri KR, Colosimo C, Eichhorn T et al. Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease. *Mov Disord* 2001; 16(2):197-201.
- (61) D'Costa DF, Abbott RJ, Pye IF, Millac PA. The apomorphine test in parkinsonian syndromes. *J Neurol Neurosurg Psychiatry* 1991; 54(10):870-872.
- (62) Hughes AJ, Lees AJ, Stern GM. Apomorphine test to predict dopaminergic responsiveness in parkinsonian syndromes. *Lancet* 1990; 336(8706):32-34.
- (63) Zappia M, Montesanti R, Colao R, Branca D, Nicoletti G, Aguglia U et al. Short-term levodopa test assessed by movement time accurately predicts dopaminergic responsiveness in Parkinson's disease. *Mov Disord* 1997; 12(1):103-106.
- (64) Winogrodzka AW. Risico op neurodegeneratieve aandoening bij idiopathische REM-slaapgebonden gedragsstoornis. *Tijdschrift voor Neurologie & Neurochirurgie* 2009; 110(2):101-102.
- (65) Ponsen MM, Stoffers D, Booij J, van Eck-Smit BL, Wolters EC, Berendse HW. Idiopathic hyposmia as a preclinical sign of Parkinson's disease. *Ann Neurol* 2004; 56(2):173-181.
- (66) Haehner A, Hummel T, Hummel C, Sommer U, Junghanns S, Reichmann H. Olfactory loss may be a first sign of idiopathic Parkinson's disease. *Mov Disord* 2007; 22(6):839-842.

- (67) Ross GW, Petrovitch H, Abbott RD, Tanner CM, Popper J, Masaki K et al. Association of olfactory dysfunction with risk for future Parkinson's disease. *Ann Neurol* 2008; 63(2):167-173.
- (68) Wakabayashi K, Takahashi H, Takeda S, Ohama E, Ikuta F. Parkinson's disease: the presence of Lewy bodies in Auerbach's and Meissner's plexuses. *Acta Neuropathol* 1988; 76(3):217-221.
- (69) Abbott RD, Petrovitch H, White LR, Masaki KH, Tanner CM, Curb JD et al. Frequency of bowel movements and the future risk of Parkinson's disease. *Neurology* 2001; 57(3):456-462.
- (70) Iranzo A, Molinuevo JL, Santamaria J, Serradell M, Marti MJ, Valldeoriola F et al. Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study. *Lancet Neurol* 2006; 5(7):572-577.
- (71) Behnke S, Berg D, Naumann M, Becker G. Differentiation of Parkinson's disease and atypical parkinsonian syndromes by transcranial ultrasound. *J Neurol Neurosurg Psychiatry* 2005; 76(3):423-425.
- (72) Tsai CF, Wu RM, Huang YW, Chen LL, Yip PK, Jeng JS. Transcranial color-coded sonography helps differentiation between idiopathic Parkinson's disease and vascular parkinsonism. *J Neurol* 2007; 254(4):501-507.
- (73) Klein C, Schlossmacher MG. The genetics of Parkinson disease: Implications for neurological care. *Nat Clin Pract Neurol* 2006; 2(3):136-146.
- (74) van de Warrenburg BP, Scheffer H, Heutink P, Bloem BR. [Parkinson's disease(s): recent insight into genetic factors]. *Ned Tijdschr Geneesk* 2007; 151(30):1665-1668.
- (75) Inerney-Leo A, Hadley DW, Gwinn-Hardy K, Hardy J. Genetic testing in Parkinson's disease. *Mov Disord* 2005; 20(1):1-10.
- (76) Nagayama H, Hamamoto M, Ueda M, Nagashima J, Katayama Y. Reliability of MIBG myocardial scintigraphy in the diagnosis of Parkinson's disease. *J Neurol Neurosurg Psychiatry* 2005; 76(2):249-251.
- (77) Taki J, Yoshita M, Yamada M, Tonami N. Significance of 123I-MIBG scintigraphy as a pathophysiological indicator in the assessment of Parkinson's disease and related disorders: it can be a specific marker for Lewy body disease. *Ann Nucl Med* 2004; 18(6):453-461.
- (78) Lee PH, Yeo SH, Kim HJ, Youm HY. Correlation between cardiac 123I-MIBG and odor identification in patients with Parkinson's disease and multiple system atrophy. *Mov Disord* 2006; 21(11):1975-1977.
- (79) Yoshita M. Differentiation of idiopathic Parkinson's disease from striatonigral degeneration and progressive supranuclear palsy using iodine-123 meta-iodobenzylguanidine myocardial scintigraphy. *J Neurol Sci* 1998; 155(1):60-67.
- (80) Vodusek DB. How to diagnose MSA early: the role of sphincter EMG. *J Neural Transm* 2005; 112(12):1657-1668.
- (81) Lee EA, Kim BJ, Lee WY. Diagnosing multiple system atrophy with greater accuracy: combined analysis of the clonidine-growth hormone test and external anal sphincter electromyography. *Mov Disord* 2002; 17(6):1242-1247.
- (82) Pellecchia MT, Pivonello R, Colao A, Barone P. Growth hormone stimulation tests in the differential diagnosis of Parkinson's disease. *Clin Med Res* 2006; 4(4):322-325.
- (83) Bonanni L, Thomas A, Tiraboschi P, Perfetti B, Varanese S, Onofri M. EEG comparisons in early Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease with dementia patients with a 2-year follow-up. *Brain* 2008; 131(Pt 3):690-705.
- (84) Muslimovic D, Schmand B, Speelman JD, de Haan RJ. Course of cognitive decline in Parkinson's disease: a meta-analysis. *J Int Neuropsychol Soc* 2007; 13(6):920-932.
- (85) Muslimovic D, Post B, Speelman JD, Schmand B. Cognitive profile of patients with newly diagnosed Parkinson disease. *Neurology* 2005; 65(8):1239-1245.
- (86) Fernandez HH, See RH, Gary MF, Bowers D, Rodriguez RL, Jacobson C et al. Depressive Symptoms in Parkinson Disease Correlate With Impaired Global and Specific Cognitive Performance. *J Geriatr Psychiatry Neurol* 2009; 22(4):223-227.
- (87) Santangelo G, Vitale C, Trojano L, Longo K, Cozzolino A, Grossi D et al. Relationship between depression and cognitive dysfunctions in Parkinson's disease without dementia. *J Neurol* 2009; 256(4):632-638.
- (88) Starkstein SE, Bolduc PL, Mayberg HS, Preziosi TJ, Robinson RG. Cognitive impairments and depression in Parkinson's disease: a follow up study. *J Neurol Neurosurg Psychiatry* 1990; 53(7):597-602.

- (89) Starkstein SE, Merello M, Jorge R, Brockman S, Bruce D, Petracca G et al. A validation study of depressive syndromes in Parkinson's disease. *Mov Disord* 2008; 23(4):538-546.
- (90) Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. *Mov Disord* 2007; 22(12):1689-1707.
- (91) Dubois B, Burn D, Goetz C, Aarsland D, Brown RG, Broe GA et al. Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force. *Mov Disord* 2007; 22(16):2314-2324.
- (92) Kulisevsky J, Pagonabarraga J. Cognitive impairment in Parkinson's disease: tools for diagnosis and assessment. *Mov Disord* 2009; 24(8):1103-1110.
- (93) Marinus J, Visser M, Verwey NA, Verhey FR, Middelkoop HA, Stiggelbout AM et al. Assessment of cognition in Parkinson's disease. *Neurology* 2003; 61(9):1222-1228.
- (94) Verbaan D, Marinus J, Visser M, van Rooden SM, Stiggelbout AM, Middelkoop HA et al. Cognitive impairment in Parkinson's disease. *J Neurol Neurosurg Psychiatry* 2007; 78(11):1182-1187.
- (95) Chaudhuri KR, Schapira AH. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. *Lancet Neurol* 2009; 8(5):464-474.
- (96) Goodman A. Organic unity theory: the mind-body problem revisited. *Am J Psychiatry* 1991; 148(5):553-563.
- (97) Simuni T, Sethi K. Nonmotor manifestations of Parkinson's disease. *Ann Neurol* 2008; 64 Suppl 2:S65-S80.
- (98) Reijnders JS, Ehrt U, Weber WE, Aarsland D, Leentjens AF. A systematic review of prevalence studies of depression in Parkinson's disease. *Mov Disord* 2008; 23(2):183-189.
- (99) Leentjens AF, Van den AM, Metsemakers JF, Lousberg R, Verhey FR. Higher incidence of depression preceding the onset of Parkinson's disease: a register study. *Mov Disord* 2003; 18(4):414-418.
- (100) Starkstein SE, Merello M, Jorge R, Brockman S, Bruce D, Petracca G et al. A validation study of depressive syndromes in Parkinson's disease. *Mov Disord* 2008; 23(4):538-546.
- (101) Nederlandse Vereniging voor Klinische Geriatrie. Richtlijn diagnostiek en medicamenteuze behandeling van dementie. Utrecht / Alphen aan de Rijn B.V.: CBO / Van Zuiden Communications (www.nvvp.net); 2005.
- (102) Marsh L, McDonald WM, Cummings J, Ravina B. Provisional diagnostic criteria for depression in Parkinson's disease: report of an NINDS/NIMH Work Group. *Mov Disord* 2006; 21(2):148-158.
- (103) Schrag A, Barone P, Brown RG, Leentjens AF, McDonald WM, Starkstein S et al. Depression rating scales in Parkinson's disease: critique and recommendations. *Mov Disord* 2007; 22(8):1077-1092.
- (104) Stacy M, Galbreath A. Optimizing long-term therapy for Parkinson disease: levodopa, dopamine agonists, and treatment-associated dyskinesia. *Clin Neuropharmacol* 2008; 31(1):51-56.
- (105) Hristova AH, Koller WC. Early Parkinson's disease: what is the best approach to treatment. *Drugs Aging* 2000; 17(3):165-181.
- (106) Imamura A, Geda YE, Slowinski J, Wszolek ZK, Brown LA, Uitti RJ. Medications used to treat Parkinson's disease and the risk of gambling. *Eur J Neurol* 2008; 15(4):350-354.
- (107) Stocchi F, Bonamartini A, Vacca L, Ruggieri S. Motor fluctuations in levodopa treatment: clinical pharmacology. *Eur Neurol* 1996; 36 Suppl 1:38-42.
- (108) Hauser RA, McDermott MP, Messing S. Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease. *Arch Neurol* 2006; 63(12):1756-1760.
- (109) Kempster PA, Williams DR, Selikhova M, Holton J, Revesz T, Lees AJ. Patterns of levodopa response in Parkinson's disease: a clinico-pathological study. *Brain* 2007; 130(Pt 8):2123-2128.
- (110) Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A et al. Levodopa and the progression of Parkinson's disease. *N Engl J Med* 2004; 351(24):2498-2508.
- (111) Safety and efficacy of pramipexole in early Parkinson disease. A randomized dose-ranging study. Parkinson Study Group. *JAMA* 1997; 278(2):125-130.
- (112) Adler CH, Sethi KD, Hauser RA, Davis TL, Hammerstad JP, Bertoni J et al. Ropinirole for the treatment of early Parkinson's disease. The Ropinirole Study Group. *Neurology* 1997; 49(2):393-399.

- (113) Barone P, Bravi D, Bermejo-Pareja F, Marconi R, Kulisevsky J, Malagu S et al. Pergolide monotherapy in the treatment of early PD: a randomized, controlled study. Pergolide Monotherapy Study Group. *Neurology* 1999; 53(3):573-579.
- (114) Brooks DJ, Abbott RJ, Lees AJ, Martignoni E, Philcox DV, Rascol O et al. A placebo-controlled evaluation of ropinirole, a novel D2 agonist, as sole dopaminergic therapy in Parkinson's disease. *Clin Neuropharmacol* 1998; 21(2):101-107.
- (115) Hubble JP, Koller WC, Cutler NR, Sramek JJ, Friedman J, Goetz C et al. Pramipexole in patients with early Parkinson's disease. *Clin Neuropharmacol* 1995; 18(4):338-347.
- (116) Shannon KM, Bennett JP, Jr., Friedman JH. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. The Pramipexole Study Group. *Neurology* 1997; 49(3):724-728.
- (117) Rascol O, Dubois B, Caldas AC, Senn S, Del SS, Lees A. Early piribedil monotherapy of Parkinson's disease: A planned seven-month report of the REGAIN study. *Mov Disord* 2006; 21(12):2110-2115.
- (118) Watts RL, Jankovic J, Waters C, Rajput A, Boroojerdi B, Rao J. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. *Neurology* 2007; 68(4):272-276.
- (119) Giladi N, Shabtai H, Gurevich T, Benbunan B, Anca M, Korczyn AD. Rivastigmine (Exelon) for dementia in patients with Parkinson's disease. *Acta Neurol Scand* 2003; 108(5):368-373.
- (120) Giladi N, Boroojerdi B, Korczyn AD, Burn DJ, Clarke CE, Schapira AH. Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole. *Mov Disord* 2007; 22(16):2398-2404.
- (121) Rascol O, Nutt JG, Blin O, Goetz CG, Trugman JM, Soubrouillard C et al. Induction by dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with Parkinson disease. *Arch Neurol* 2001; 58(2):249-254.
- (122) Rasmussen VG, Poulsen SH, Dupont E, Ostergaard K, Safikhany G, Egeblad H. Heart valve disease associated with treatment with ergot-derived dopamine agonists: a clinical and echocardiographic study of patients with Parkinson's disease. *J Intern Med* 2008; 263(1):90-98.
- (123) Dhawan V, Medcalf P, Stegie F, Jackson G, Basu S, Luce P et al. Retrospective evaluation of cardio-pulmonary fibrotic side effects in symptomatic patients from a group of 234 Parkinson's disease patients treated with cabergoline. *J Neural Transm* 2005; 112(5):661-668.
- (124) Antonini A, Poewe W. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease. *Lancet Neurol* 2007; 6(9):826-829.
- (125) Paus S, Brecht HM, Koster J, Seeger G, Klockgether T, Wullner U. Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease. *Mov Disord* 2003; 18(6):659-667.
- (126) Homann CN, Wenzel K, Suppan K, Ivanic G, Kriechbaum N, Crevenna R et al. Sleep attacks in patients taking dopamine agonists: review. *BMJ* 2002; 324(7352):1483-1487.
- (127) Chaudhuri KR, Pal S, Brefel-Courbon C. 'Sleep attacks' or 'unintended sleep episodes' occur with dopamine agonists: is this a class effect? *Drug Saf* 2002; 25(7):473-483.
- (128) Thobois S. Proposed dose equivalence for rapid switch between dopamine receptor agonists in Parkinson's disease: a review of the literature. *Clin Ther* 2006; 28(1):1-12.
- (129) Takahashi H, Nogawa S, Tachibana H, Kawamura J, Abe T, Ogino Y et al. Pramipexole safely replaces ergot dopamine agonists with either rapid or slow switching. *J Int Med Res* 2008; 36(1):106-114.
- (130) Grosset K, Needleman F, Macphee G, Grosset D. Switching from ergot to nonergot dopamine agonists in Parkinson's disease: a clinical series and five-drug dose conversion table. *Mov Disord* 2004; 19(11):1370-1374.
- (131) Reichmann H, Odin P, Brecht HM, Koster J, Kraus PH. Changing dopamine agonist treatment in Parkinson's disease: experiences with switching to pramipexole. *J Neural Transm Suppl* 2006;(71):17-25.
- (132) Canesi M, Antonini A, Mariani CB, Tesi S, Zecchinelli AL, Barichella M et al. An overnight switch to ropinirole therapy in patients with Parkinson's disease. Short communication. *J Neural Transm* 1999; 106(9-10):925-929.
- (133) Ives NJ, Stowe RL, Marro J, Counsell C, Macleod A, Clarke CE et al. Monoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patients. *BMJ* 2004; 329(7466):593.

- (134) Macleod AD, Counsell CE, Ives N, Stowe R. Monoamine oxidase B inhibitors for early Parkinson's disease. *Cochrane Database Syst Rev* 2005;(3):CD004898.
- (135) Presthus J, Berstad J, Lien K. Selegiline (1-deprenyl) and low-dose levodopa treatment of Parkinson's disease. A double-blind crossover trial. *Acta Neurol Scand* 1987; 76(3):200-203.
- (136) Stern MB, Marek KL, Friedman J, Hauser RA, LeWitt PA, Tarsy D et al. Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients. *Mov Disord* 2004; 19(8):916-923.
- (137) Elmer L, Schwid S, Eberly S, Goetz C, Fahn S, Kieburtz K et al. Rasagiline-associated motor improvement in PD occurs without worsening of cognitive and behavioral symptoms. *J Neurol Sci* 2006; 248(1-2):78-83.
- (138) Biglan KM, Schwid S, Eberly S, Blindauer K, Fahn S, Goren T et al. Rasagiline improves quality of life in patients with early Parkinson's disease. *Mov Disord* 2006; 21(5):616-623.
- (139) Fernandez HH, Chen JJ. Monoamine oxidase-B inhibition in the treatment of Parkinson's disease. *Pharmacotherapy* 2007; 27(12 Pt 2):174S-185S.
- (140) Thorpy MJ, Adler CH. Parkinson's disease and sleep. *Neurol Clin* 2005; 23(4):1187-1208.
- (141) Stoof JC, Booij J, Drukarch B. Amantadine as N-methyl-D-aspartic acid receptor antagonist: new possibilities for therapeutic applications? *Clin Neurol Neurosurg* 1992; 94 Suppl:S4-S6.
- (142) Crosby N, Deane KH, Clarke CE. Amantadine in Parkinson's disease. *Cochrane Database Syst Rev* 2003;(1):CD003468.
- (143) Sage JI, Mark MH. Pharmacokinetics of continuous-release carbidopa/levodopa. *Clin Neuropharmacol* 1994; 17 Suppl 2:S1-S6.
- (144) Block G, Liss C, Reines S, Irr J, Nibbelink D. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group. *Eur Neurol* 1997; 37(1):23-27.
- (145) Dupont E, Andersen A, Boas J, Boisen E, Borgmann R, Helgetveit AC et al. Sustained-release Madopar HBS compared with standard Madopar in the long-term treatment of de novo parkinsonian patients. *Acta Neurol Scand* 1996; 93(1):14-20.
- (146) Pahwa R, Busenbark K, Huber SJ, Michalek D, Hubble JP, Koller WC. Clinical experience with controlled-release carbidopa/levodopa in Parkinson's disease. *Neurology* 1993; 43(4):677-681.
- (147) Crosby NJ, Deane KH, Clarke CE. Beta-blocker therapy for tremor in Parkinson's disease. *Cochrane Database Syst Rev* 2003;(1):CD003361.
- (148) Claveria L, Vakil S, George C, et al. Oxprenolol in Parkinsonism. *Journal of Clinical Pharmacology* 2007; 15:66-68.
- (149) Brooks JO, Hoblyn JC. Neurocognitive costs and benefits of psychotropic medications in older adults. *J Geriatr Psychiatry Neurol* 2007; 20(4):199-214.
- (150) Katzenschlager R, Sampaio C, Costa J, Lees A. Anticholinergics for symptomatic management of Parkinson's disease. *Cochrane Database Syst Rev* 2003;(2):CD003735.
- (151) Cooper JA, Sagar HJ, Doherty SM, Jordan N, Tidswell P, Sullivan EV. Different effects of dopaminergic and anticholinergic therapies on cognitive and motor function in Parkinson's disease. A follow-up study of untreated patients. *Brain* 1992; 115 (Pt 6):1701-1725.
- (152) Perry EK, Perry RH. Acetylcholine and hallucinations: disease-related compared to drug-induced alterations in human consciousness. *Brain Cogn* 1995; 28(3):240-258.
- (153) Hely MA, Morris JG, Reid WG, O'Sullivan DJ, Williamson PM, Rail D et al. The Sydney Multicentre Study of Parkinson's disease: a randomised, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa. *J Neurol Neurosurg Psychiatry* 1994; 57(8):903-910.
- (154) Caraceni T, Musicco M. Levodopa or dopamine agonists, or deprenyl as initial treatment for Parkinson's disease. A randomized multicenter study. *Parkinsonism Relat Disord* 2001; 7(2):107-114.
- (155) Kostic V, Przedborski S, Flaster E, Sternic N. Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease. *Neurology* 1991; 41(2 (Pt 1)):202-205.
- (156) Constantinescu R, Romer M, McDermott MP, Kamp C, Kieburtz K. Impact of pramipexole on the onset of levodopa-related dyskinesias. *Mov Disord* 2007; 22(9):1317-1319.
- (157) Kostic VS, Marinkovic J, Svetel M, Stefanova E, Przedborski S. The effect of stage of Parkinson's disease at the onset of levodopa therapy on development of motor complications. *Eur J Neurol* 2002; 9(1):9-14.

- (158) Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. *N Engl J Med* 2000; 342(20):1484-1491.
- (159) Bloem BR, Beckley DJ, van Dijk JG, Zwinderman AH, Remler MP, Roos RA. Influence of dopaminergic medication on automatic postural responses and balance impairment in Parkinson's disease. *Mov Disord* 1996; 11(5):509-521.
- (160) Koller WC. Initiating treatment of Parkinson's disease. *Neurology* 1992; 42(1 Suppl 1):33-38.
- (161) Olanow CW, Agid Y, Mizuno Y, Albanese A, Bonuccelli U, Damier P et al. Levodopa in the treatment of Parkinson's disease: current controversies. *Mov Disord* 2004; 19(9):997-1005.
- (162) Kumar N, Van Gerpen JA, Bower JH, Ahlskog JE. Levodopa-dyskinesia incidence by age of Parkinson's disease onset. *Mov Disord* 2005; 20(3):342-344.
- (163) Van Gerpen JA, Kumar N, Bower JH, Weigand S, Ahlskog JE. Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976-1990. *Arch Neurol* 2006; 63(2):205-209.
- (164) Clissold BG, McColl CD, Reardon KR, Shiff M, Kempster PA. Longitudinal study of the motor response to levodopa in Parkinson's disease. *Mov Disord* 2006; 21(12):2116-2121.
- (165) Mouradian MM, Heuser IJ, Baronti F, Fabbrini G, Juncos JL, Chase TN. Pathogenesis of dyskinesias in Parkinson's disease. *Ann Neurol* 1989; 25(5):523-526.
- (166) Katzenschlager R, Head J, Schrag A, Ben-Shlomo Y, Evans A, Lees AJ. Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. *Neurology* 2008; 71(7):474-480.
- (167) Ahlskog JE, Muenter MD, McManis PG, Bell GN, Bailey PA. Controlled-release Sinemet (CR-4): a double-blind crossover study in patients with fluctuating Parkinson's disease. *Mayo Clin Proc* 1988; 63(9):876-886.
- (168) Cedarbaum JM, Hoey M, McDowell FH. A double-blind crossover comparison of Sinemet CR4 and standard Sinemet 25/100 in patients with Parkinson's disease and fluctuating motor performance. *J Neurol Neurosurg Psychiatry* 1989; 52(2):207-212.
- (169) Feldman RG, Mosbach PA, Kelly MR, Thomas CA, Saint Hilaire MH. Double-blind comparison of standard Sinemet and Sinemet CR in patients with mild-to-moderate Parkinson's disease. *Neurology* 1989; 39(11 Suppl 2):96-101.
- (170) Hutton JT, Morris JL, Roman GC, Imke SC, Elias JW. Treatment of chronic Parkinson's disease with controlled-release carbidopa/levodopa. *Arch Neurol* 1988; 45(8):861-864.
- (171) Hutton JT, Morris JL, Bush DF, Smith ME, Liss CL, Reines S. Multicenter controlled study of Sinemet CR vs Sinemet (25/100) in advanced Parkinson's disease. *Neurology* 1989; 39(11 Suppl 2):67-72.
- (172) Juncos JL, Fabbrini G, Mouradian MM, Chase TN. Controlled release levodopa-carbidopa (CR-5) in the management of parkinsonian motor fluctuations. *Arch Neurol* 1987; 44(10):1010-1012.
- (173) LeWitt PA, Nelson MV, Berchou RC, Galloway MP, Kesaree N, Kreti D et al. Controlled-release carbidopa/levodopa (Sinemet 50/200 CR4): clinical and pharmacokinetic studies. *Neurology* 1989; 39(11 Suppl 2):45-53.
- (174) Lieberman A, Gopinathan G, Miller E, Neophytides A, Baumann G, Chin L. Randomized double-blind cross-over study of Sinemet-controlled release (CR4 50/200) versus Sinemet 25/100 in Parkinson's disease. *Eur Neurol* 1990; 30(2):75-78.
- (175) Sage JI, Mark MH. Comparison of controlled-release Sinemet (CR4) and standard Sinemet (25 mg/100 mg) in advanced Parkinson's disease: a double-blind, crossover study. *Clin Neuropharmacol* 1988; 11(2):174-179.
- (176) Wolters EC, Horstink MW, Roos RA, Jansen EN. Clinical efficacy of Sinemet CR 50/200 versus Sinemet 25/100 in patients with fluctuating Parkinson's disease. An open, and a double-blind, double-dummy, multicenter treatment evaluation. The Dutch Sinemet CR Study Group. *Clin Neurol Neurosurg* 1992; 94(3):205-211.
- (177) Wolters EC, Tesselaar HJ. International (NL-UK) double-blind study of Sinemet CR and standard Sinemet (25/100) in 170 patients with fluctuating Parkinson's disease. *J Neurol* 1996; 243(3):235-240.
- (178) Clarke CE, Speller JM. Lisuride for levodopa-induced complications in Parkinson's disease. *Cochrane Database Syst Rev* 2000;(2):CD001515.
- (179) Clarke CE, Speller JM. Pergolide versus bromocriptine for levodopa-induced motor complications in Parkinson's disease. *Cochrane Database Syst Rev* 2000;(2):CD000236.
- (180) Clarke CE, Speller JM, Clarke JA. Pramipexole for levodopa-induced complications in Parkinson's disease. *Cochrane Database Syst Rev* 2000;(3):CD002261.

- (181) Clarke CE, Deane KH. Cabergoline for levodopa-induced complications in Parkinson's disease. *Cochrane Database Syst Rev* 2001;(1):CD001518.
- (182) Clarke CE, Deane KH. Ropinirole for levodopa-induced complications in Parkinson's disease. *Cochrane Database Syst Rev* 2001;(1):CD001516.
- (183) van Hilten JJ, Ramaker C, Van de Beek WJ, Finken MJ. Bromocriptine for levodopa-induced motor complications in Parkinson's disease. *Cochrane Database Syst Rev* 2000;(2):CD001203.
- (184) Mizuno Y, Yanagisawa N, Kuno S, Yamamoto M, Hasegawa K, Origasa H et al. Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease. *Mov Disord* 2003; 18(10):1149-1156.
- (185) Pogarell O, Gasser T, van Hilten JJ, Spieker S, Pollentier S, Meier D et al. Pramipexole in patients with Parkinson's disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre study. *J Neurol Neurosurg Psychiatry* 2002; 72(6):713-720.
- (186) Wong KS, Lu CS, Shan DE, Yang CC, Tsoi TH, Mok V. Efficacy, safety, and tolerability of pramipexole in untreated and levodopa-treated patients with Parkinson's disease. *J Neurol Sci* 2003; 216(1):81-87.
- (187) Barone P, Lamb J, Ellis A, Clarke Z. Sumanriole versus placebo or ropinirole for the adjunctive treatment of patients with advanced Parkinson's disease. *Mov Disord* 2007; 22(4):483-489.
- (188) LeWitt PA, Lyons KE, Pahwa R. Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study. *Neurology* 2007; 68(16):1262-1267.
- (189) Pahwa R, Stacy MA, Factor SA, Lyons KE, Stocchi F, Hersh BP et al. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. *Neurology* 2007; 68(14):1108-1115.
- (190) Poewe WH, Rascol O, Quinn N, Tolosa E, Oertel WH, Martignoni E et al. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. *Lancet Neurol* 2007; 6(6):513-520.
- (191) Moller JC, Oertel WH, Koster J, Pezzoli G, Provinciali L. Long-term efficacy and safety of pramipexole in advanced Parkinson's disease: results from a European multicenter trial. *Mov Disord* 2005; 20(5):602-610.
- (192) Goetz CG, Poewe W, Rascol O, Sampaio C. Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. *Mov Disord* 2005; 20(5):523-539.
- (193) A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. *Arch Neurol* 2005; 62(2):241-248.
- (194) Brodersen P, Philbert A, Gulliksen G, Stigard A. The effect of L-Deprenyl on on-off phenomena in Parkinson's disease. *Acta Neurol Scand* 1985; 71(6):494-497.
- (195) Golbe LI, Duvoisin RC. Double-blind trial of R-(-)-deprenyl for the "on-off" effect complicating Parkinson's disease. *J Neural Transm Suppl* 1987; 25:123-129.
- (196) Golbe LI, Lieberman AN, Muentzer MD, Ahlskog JE, Gopinathan G, Neophytides AN et al. Deprenyl in the treatment of symptom fluctuations in advanced Parkinson's disease. *Clin Neuropharmacol* 1988; 11(1):45-55.
- (197) Hubble JP, Koller WC, Waters C. Effects of selegiline dosing on motor fluctuations in Parkinson's disease. *Clin Neuropharmacol* 1993; 16(1):83-87.
- (198) Lieberman AN, Gopinathan G, Neophytides A, Foo SH. Deprenyl versus placebo in Parkinson disease: a double-blind study. *N Y State J Med* 1987; 87(12):646-649.
- (199) Rascol O, Brooks DJ, Melamed E, Oertel W, Poewe W, Stocchi F et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. *Lancet* 2005; 365(9463):947-954.
- (200) Sivertsen B, Dupont E, Mikkelsen B, Mogensen P, Rasmussen C, Boesen F et al. Selegiline and levodopa in early or moderately advanced Parkinson's disease: a double-blind controlled short- and long-term study. *Acta Neurol Scand Suppl* 1989; 126:147-152.
- (201) Waters CH, Sethi KD, Hauser RA, Molho E, Bertoni JM. Zydys selegiline reduces off time in Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study. *Mov Disord* 2004; 19(4):426-432.

- (202) Presthus J, Hajba A. Deprenyl (selegiline) combined with levodopa and a decarboxylase inhibitor in the treatment of Parkinson's disease. *Acta Neurol Scand Suppl* 1983; 95:127-133.
- (203) Deane KH, Spieker S, Clarke CE. Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease. *Cochrane Database Syst Rev* 2004;(4):CD004554.
- (204) Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Parkinson Study Group. *Ann Neurol* 1997; 42(5):747-755.
- (205) Adler CH, Singer C, O'Brien C, Hauser RA, Lew MF, Marek KL et al. Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Tolcapone Fluctuator Study Group III. *Arch Neurol* 1998; 55(8):1089-1095.
- (206) Baas H, Beiske AG, Ghika J, Jackson M, Oertel WH, Poewe W et al. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients. *J Neurol Neurosurg Psychiatry* 1997; 63(4):421-428.
- (207) Brooks DJ, Sagar H. Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study. *J Neurol Neurosurg Psychiatry* 2003; 74(8):1071-1079.
- (208) Dupont E, Burgunder JM, Findley LJ, Olsson JE, Dorflinger E. Tolcapone added to levodopa in stable parkinsonian patients: a double-blind placebo-controlled study. Tolcapone in Parkinson's Disease Study Group II (TIPS II). *Mov Disord* 1997; 12(6):928-934.
- (209) Kurth MC, Adler CH, Hilaire MS, Singer C, Waters C, LeWitt P et al. Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Tolcapone Fluctuator Study Group I. *Neurology* 1997; 48(1):81-87.
- (210) Myllyla VV, Kultalahti ER, Haapaniemi H, Leinonen M. Twelve-month safety of entacapone in patients with Parkinson's disease. *Eur J Neurol* 2001; 8(1):53-60.
- (211) Poewe WH, Deuschl G, Gordin A, Kultalahti ER, Leinonen M. Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). *Acta Neurol Scand* 2002; 105(4):245-255.
- (212) Rajput AH, Martin W, Saint-Hilaire MH, Dorflinger E, Pedder S. Tolcapone improves motor function in parkinsonian patients with the "wearing-off" phenomenon: a double-blind, placebo-controlled, multicenter trial. *Neurology* 1997; 49(4):1066-1071.
- (213) Rinne UK, Larsen JP, Siden A, Worm-Petersen J. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group. *Neurology* 1998; 51(5):1309-1314.
- (214) Reichmann H, Boas J, Macmahon D, Myllyla V, Hakala A, Reinikainen K. Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuations. *Acta Neurol Scand* 2005; 111(1):21-28.
- (215) Mizuno Y, Kanazawa I, Kuno S, Yanagisawa N, Yamamoto M, Kondo T. Placebo-controlled, double-blind dose-finding study of entacapone in fluctuating parkinsonian patients. *Mov Disord* 2007; 22(1):75-80.
- (216) Deane KH, Spieker S, Clarke CE. Catechol-O-methyltransferase inhibitors versus active comparators for levodopa-induced complications in Parkinson's disease. *Cochrane Database Syst Rev* 2004;(4):CD004553.
- (217) Agid Y, Destee A, Durif F, Montastruc JL, Pollak P. Tolcapone, bromocriptine, and Parkinson's disease. French Tolcapone Study Group. *Lancet* 1997; 350(9079):712-713.
- (218) Verhagen ML, Del DP, van den MP, Fang J, Mouradian MM, Chase TN. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. *Neurology* 1998; 50(5):1323-1326.
- (219) Crosby NJ, Deane KH, Clarke CE. Amantadine for dyskinesia in Parkinson's disease. *Cochrane Database Syst Rev* 2003;(2):CD003467.
- (220) Thomas A, Iacono D, Luciano AL, Armellino K, Di IA, Onofri M. Duration of amantadine benefit on dyskinesia of severe Parkinson's disease. *J Neurol Neurosurg Psychiatry* 2004; 75(1):141-143.
- (221) Lugging E, Wenning GK, Bosch S, Poewe W. Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's disease. *Mov Disord* 2000; 15(5):873-878.

- (222) Dewey RB, Jr., Hutton JT, LeWitt PA, Factor SA. A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events. *Arch Neurol* 2001; 58(9):1385-1392.
- (223) Ostergaard L, Werdelin L, Odin P, Lindvall O, Dupont E, Christensen PB et al. Pen injected apomorphine against off phenomena in late Parkinson's disease: a double blind, placebo controlled study. *J Neurol Neurosurg Psychiatry* 1995; 58(6):681-687.
- (224) van LT, Jansen EN, Essink AW, Neef C, Oosterloo S, Roos RA. A double-blind study of the efficacy of apomorphine and its assessment in 'off-periods in Parkinson's disease. *Clin Neurol Neurosurg* 1993; 95(3):231-235.
- (225) Colzi A, Turner K, Lees AJ. Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease. *J Neurol Neurosurg Psychiatry* 1998; 64(5):573-576.
- (226) Frankel JP, Lees AJ, Kempster PA, Stern GM. Subcutaneous apomorphine in the treatment of Parkinson's disease. *J Neurol Neurosurg Psychiatry* 1990; 53(2):96-101.
- (227) Gancher ST, Nutt JG, Woodward WR. Apomorphine infusional therapy in Parkinson's disease: clinical utility and lack of tolerance. *Mov Disord* 1995; 10(1):37-43.
- (228) Hughes AJ, Bishop S, Kleedorfer B, Turjanski N, Fernandez W, Lees AJ et al. Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years. *Mov Disord* 1993; 8(2):165-170.
- (229) Kanovsky P, Kubova D, Bares M, Hortova H, Streitova H, Rektor I et al. Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: results of a two-year, prospective follow-up. *Mov Disord* 2002; 17(1):188-191.
- (230) Manson AJ, Turner K, Lees AJ. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients. *Mov Disord* 2002; 17(6):1235-1241.
- (231) Pietz K, Hagell P, Odin P. Subcutaneous apomorphine in late stage Parkinson's disease: a long term follow up. *J Neurol Neurosurg Psychiatry* 1998; 65(5):709-716.
- (232) Poewe W, Kleedorfer B, Wagner M, Bosch S, Schelosky L. Continuous subcutaneous apomorphine infusions for fluctuating Parkinson's disease. Long-term follow-up in 18 patients. *Adv Neurol* 1993; 60:656-659.
- (233) Stocchi F, Vacca L, De Pandis MF, Barbato L, Valente M, Ruggieri S. Subcutaneous continuous apomorphine infusion in fluctuating patients with Parkinson's disease: long-term results. *Neurol Sci* 2001; 22(1):93-94.
- (234) Katzenschlager R, Hughes A, Evans A, Manson AJ, Hoffman M, Swinn L et al. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges. *Mov Disord* 2005; 20(2):151-157.
- (235) Nyholm D, Askmark H, Gomes-Trolin C, Knutson T, Lennernas H, Nystrom C et al. Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets. *Clin Neuropharmacol* 2003; 26(3):156-163.
- (236) Nyholm D, Nilsson Remahl AI, Dizdar N, Constantinescu R, Holmberg B, Jansson R et al. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. *Neurology* 2005; 64(2):216-223.
- (237) Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. *Mov Disord* 2008; 23(15):2129-2170.
- (238) Marinus J, Visser M, Martinez-Martin P, van Hilten JJ, Stiggelbout AM. A short psychosocial questionnaire for patients with Parkinson's disease: the SCOPA-PS. *J Clin Epidemiol* 2003; 56(1):61-67.
- (239) Marinus J, Visser M, van Hilten JJ, Lammers GJ, Stiggelbout AM. Assessment of sleep and sleepiness in Parkinson disease. *Sleep* 2003; 26(8):1049-1054.
- (240) Marinus J, Visser M, Stiggelbout AM, Rabey JM, Martinez-Martin P, Bonuccelli U et al. A short scale for the assessment of motor impairments and disabilities in Parkinson's disease: the SPES/SCOPA. *J Neurol Neurosurg Psychiatry* 2004; 75(3):388-395.
- (241) Visser M, Marinus J, Stiggelbout AM, van Hilten JJ. Assessment of autonomic dysfunction in Parkinson's disease: the SCOPA-AUT. *Mov Disord* 2004; 19(11):1306-1312.
- (242) Visser M, Verbaan D, van Rooden SM, Stiggelbout AM, Marinus J, van Hilten JJ. Assessment of psychiatric complications in Parkinson's disease: The SCOPA-PC. *Mov Disord* 2007; 22(15):2221-2228.

- (243) Hauser RA, Russ H, Haeger DA, Bruguiera-Fontenille M, Muller T, Wenning GK. Patient evaluation of a home diary to assess duration and severity of dyskinesia in Parkinson disease. *Clin Neuropharmacol* 2006; 29(6):322-330.
- (244) Reimer J, Grabowski M, Lindvall O, Hagell P. Use and interpretation of on/off diaries in Parkinson's disease. *J Neurol Neurosurg Psychiatry* 2004; 75(3):396-400.
- (245) Ghazi-Noori S, Chung TH, Deane KHO, Rickards H, Clarke CE. Therapies for depression in Parkinson's disease. *The Cochrane Library* 2004;(Issue 3).
- (246) Weintraub D, Morales KH, Moberg PJ, Bilker WB, Balderston C, Duda JE et al. Antidepressant studies in Parkinson's disease: a review and meta-analysis. *Mov Disord* 2005; 20(9):1161-1169.
- (247) Devos D, Dujardin K, Poirot I, Moreau C, Cottencin O, Thomas P et al. Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study. *Mov Disord* 2008; 23(6):850-857.
- (248) Shabnam GN, Th C, Kho D, H R, Ce C. Therapies for depression in Parkinson's disease. *Cochrane Database Syst Rev* 2003;(3):CD003465.
- (249) Multidisciplinaire richtlijn depressie; Richtlijn voor de diagnostiek en behandeling van volwassen cliënten met depressie. www.cbo.nl [2005
- (250) Buchwald B, Angersbach D, Jost WH. [Improvements in motor and non-motor symptoms in parkinson patients under ropinirole therapy]. *Fortschr Neurol Psychiatr* 2007; 75(4):236-241.
- (251) Navan P, Findley LJ, Jeffs JA, Pearce RK, Bain PG. Randomized, double-blind, 3-month parallel study of the effects of pramipexole, pergolide, and placebo on Parkinsonian tremor. *Mov Disord* 2003; 18(11):1324-1331.
- (252) Rektorova I, Rektor I, Bares M, Dostal V, Ehler E, Fanfrdlova Z et al. Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study. *Eur J Neurol* 2003; 10(4):399-406.
- (253) Cole K, Vaughan FL. The feasibility of using cognitive behaviour therapy for depression associated with Parkinson's disease: a literature review. *Parkinsonism Relat Disord* 2005; 11(5):269-276.
- (254) Dobkin RD, Allen LA, Menza M. Cognitive-behavioral therapy for depression in Parkinson's disease: a pilot study. *Mov Disord* 2007; 22(7):946-952.
- (255) Dobkin RD, Menza M, Bienfait KL. CBT for the treatment of depression in Parkinson's disease: a promising nonpharmacological approach. *Expert Rev Neurother* 2008; 8(1):27-35.
- (256) Dreisig H, Beckmann J, Wermuth L, Skovlund S, Bech P. Psychologic effects of structured cognitive psychotherapy in young patients with Parkinson disease: A pilot study. *Nord J Psychiatry* 1999; 53:217-221.
- (257) Secker DL, Brown RG. Cognitive behavioural therapy (CBT) for carers of patients with Parkinson's disease: a preliminary randomised controlled trial. *J Neurol Neurosurg Psychiatry* 2005; 76(4):491-497.
- (258) Graham JM, Grunewald RA, Sagar HJ. Hallucinosi in idiopathic Parkinson's disease. *J Neurol Neurosurg Psychiatry* 1997; 63(4):434-440.
- (259) Collerton D, Perry E, McKeith I. Why people see things that are not there: a novel Perception and Attention Deficit model for recurrent complex visual hallucinations. *Behav Brain Sci* 2005; 28(6):737-757.
- (260) Meppelink AM, de Jong BM, Renken R, Leenders KL, Cornelissen FW, van LT. Impaired visual processing preceding image recognition in Parkinson's disease patients with visual hallucinations. *Brain* 2009; 132(Pt 11):2980-2993.
- (261) Breier A, Sutton VK, Feldman PD, Kadam DL, Ferchland I, Wright P et al. Olanzapine in the treatment of dopaminergic-induced psychosis in patients with Parkinson's disease. *Biol Psychiatry* 2002; 52(5):438-445.
- (262) Friedman J, Lannon M, Comella C, Factor S, Kurlan R, Richard I et al. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. *New England Journal of Medicine* 1999; 340(10):757-763.
- (263) Morgante L, Epifanio A, Spina E, Zappia M, Di Rosa AE, Marconi R et al. Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis. *Clin Neuropharmacol* 2004; 27(4):153-156.
- (264) Ondo WG, Levy JK, Vuong KD, Hunter C, Jankovic J. Olanzapine treatment for dopaminergic-induced hallucinations. *Movement Disorders* 2002; 17(5):1031-1035.

- (265) Ondo WG, Tintner R, Voung KD, Lai D, Ringholz G. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease. *Mov Disord* 2005; 20(8):958-963.
- (266) Pollak P, Tison F, Rascol O, Destee A, Pere JJ, Senard JM et al. Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up. *J Neurol Neurosurg Psychiatry* 2004; 75(5):689-695.
- (267) Rabey JM, Prokhorov T, Miniovitz A, Dobronevsky E, Klein C. Effect of quetiapine in psychotic Parkinson's disease patients: a double-blind labeled study of 3 months' duration. *Mov Disord* 2007; 22(3):313-318.
- (268) Zahodne LB, Fernandez HH. Course, prognosis, and management of psychosis in Parkinson's disease: are current treatments really effective? *CNS Spectr* 2008; 13(3 Suppl 4):26-33.
- (269) Williams-Gray CH, Foltynie T, Lewis SJ, Barker RA. Cognitive deficits and psychosis in Parkinson's disease: a review of pathophysiology and therapeutic options. *CNS Drugs* 2006; 20(6):477-505.
- (270) Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. *Arch Neurol* 2003; 60(3):387-392.
- (271) Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP et al. Rivastigmine for dementia associated with Parkinson's disease. *N Engl J Med* 2004; 351(24):2509-2518.
- (272) Burn D, Emre M, McKeith I, De Deyn PP, Aarsland D, Hsu C et al. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. *Mov Disord* 2006; 21(11):1899-1907.
- (273) Poewe W, Wolters E, Emre M, Onofrij M, Hsu C, Tekin S et al. Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study. *Mov Disord* 2006; 21(4):456-461.
- (274) Winblad B, Grossberg G, Frolich L, Farlow M, Zechner S, Nagel J et al. IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease. *Neurology* 2007; 69(4 Suppl 1):S14-S22.
- (275) Aarsland D, Hutchinson M, Larsen JP. Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia. *Int J Geriatr Psychiatry* 2003; 18(10):937-941.
- (276) Minett TS, Thomas A, Wilkinson LM, Daniel SL, Sanders J, Richardson J et al. What happens when donepezil is suddenly withdrawn? An open label trial in dementia with Lewy bodies and Parkinson's disease with dementia. *Int J Geriatr Psychiatry* 2003; 18(11):988-993.
- (277) Voon V, Hassan K, Zurowski M, de SM, Thomsen T, Fox S et al. Prevalence of repetitive and reward-seeking behaviors in Parkinson disease. *Neurology* 2006; 67(7):1254-1257.
- (278) Voon V, Hassan K, Zurowski M, Duff-Canning S, de SM, Fox S et al. Prospective prevalence of pathologic gambling and medication association in Parkinson disease. *Neurology* 2006; 66(11):1750-1752.
- (279) Weintraub D, Siderowf AD, Potenza MN, Goveas J, Morales KH, Duda JE et al. Association of dopamine agonist use with impulse control disorders in Parkinson disease. *Arch Neurol* 2006; 63(7):969-973.
- (280) Evans AH, Katzenschlager R, Paviour D, O'Sullivan JD, Appel S, Lawrence AD et al. Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome. *Mov Disord* 2004; 19(4):397-405.
- (281) Pontone G, Williams JR, Bassett SS, Marsh L. Clinical features associated with impulse control disorders in Parkinson disease. *Neurology* 2006; 67(7):1258-1261.
- (282) Voon V, Thomsen T, Miyasaki JM, de SM, Shafrro A, Fox SH et al. Factors associated with dopaminergic drug-related pathological gambling in Parkinson disease. *Arch Neurol* 2007; 64(2):212-216.
- (283) Blaszczynski A, Steel Z, McConaghy N. Impulsivity in pathological gambling: the antisocial impulsivist. *Addiction* 1997; 92(1):75-87.
- (284) Petry NM. Substance abuse, pathological gambling, and impulsiveness. *Drug Alcohol Depend* 2001; 63(1):29-38.
- (285) Chambers RA, Potenza MN. Neurodevelopment, impulsivity, and adolescent gambling. *J Gambl Stud* 2003; 19(1):53-84.
- (286) Potenza MN, Voon V, Weintraub D. Drug Insight: impulse control disorders and dopamine therapies in Parkinson's disease. *Nat Clin Pract Neurol* 2007; 3(12):664-672.

- (287) Mamikonyan E, Siderowf AD, Duda JE, Potenza MN, Horn S, Stern MB et al. Long-term follow-up of impulse control disorders in Parkinson's disease. *Mov Disord* 2008; 23(1):75-80.
- (288) Jarman B, Hurwitz B, Cook A, Bajekal M, Lee A. Effects of community based nurses specialising in Parkinson's disease on health outcome and costs: randomised controlled trial. *British Medical Journal* 2002; 324(7345):1072-1075.
- (289) Clarke CE, Guttman M. Dopamine agonist monotherapy in Parkinson's disease. *Lancet* 2002; 360(9347):1767-1769.
- (290) Michell AW, Lewis SJ, Foltynie T, Barker RA. Biomarkers and Parkinson's disease. *Brain* 2004; 127(Pt 8):1693-1705.
- (291) Clarke CE. Neuroprotection and pharmacotherapy for motor symptoms in Parkinson's disease. *Lancet Neurol* 2004; 3(8):466-474.
- (292) Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. The Parkinson Study Group. *N Engl J Med* 1993; 328(3):176-183.
- (293) Kieburtz K, McDermott M, Como P, Growdon J, Brady J, Carter J et al. The effect of deprenyl and tocopherol on cognitive performance in early untreated Parkinson's disease. Parkinson Study Group. *Neurology* 1994; 44(9):1756-1759.
- (294) Shults CW. Effect of selegiline (deprenyl) on the progression of disability in early Parkinson's disease. Parkinson Study Group. *Acta Neurol Scand Suppl* 1993; 146:36-42.
- (295) Shoulson I. Deprenyl and tocopherol antioxidative therapy of parkinsonism (DATATOP). Parkinson Study Group. *Acta Neurol Scand Suppl* 1989; 126:171-175.
- (296) Muller T, Buttner T, Gholipour AF, Kuhn W. Coenzyme Q10 supplementation provides mild symptomatic benefit in patients with Parkinson's disease. *Neurosci Lett* 2003; 341(3):201-204.
- (297) Shults CW, Oakes D, Kieburtz K, Beal MF, Haas R, Plumb S et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. *Arch Neurol* 2002; 59(10):1541-1550.
- (298) Storch A, Jost WH, Vieregge P, Spiegel J, Greulich W, Durner J et al. Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease. *Arch Neurol* 2007; 64(7):938-944.
- (299) A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease. *Neurology* 2007; 68(1):20-28.
- (300) Hely MA, Morris JG, Traficante R, Reid WG, O'Sullivan DJ, Williamson PM. The sydney multicentre study of Parkinson's disease: progression and mortality at 10 years. *J Neurol Neurosurg Psychiatry* 1999; 67(3):300-307.
- (301) Marek K, Jennings D, Seibyl J. Do dopamine agonists or levodopa modify Parkinson's disease progression? *Eur J Neurol* 2002; 9 Suppl 3:15-22.
- (302) Montastruc JL, Desboeuf K, Lapeyre-Mestre M, Senard JM, Rascol O, Brefel-Courbon C. Long-term mortality results of the randomized controlled study comparing bromocriptine to which levodopa was later added with levodopa alone in previously untreated patients with Parkinson's disease. *Mov Disord* 2001; 16(3):511-514.
- (303) Przuntek H, Welzel D, Blumner E, Danielczyk W, Letzel H, Kaiser HJ et al. Bromocriptine lessens the incidence of mortality in L-dopa-treated parkinsonian patients: prado-study discontinued. *Eur J Clin Pharmacol* 1992; 43(4):357-363.
- (304) Whone AL, Watts RL, Stoessl AJ, Davis M, Reske S, Nahmias C et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. *Ann Neurol* 2003; 54(1):93-101.
- (305) Rinne UK, Bracco F, Chouza C, Dupont E, Gershanik O, Marti Masso JF et al. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group. *Drugs* 1998; 55 Suppl 1:23-30.
- (306) Oertel WH, Wolters E, Sampaio C, Gimenez-Roldan S, Bergamasco B, Dujardin M et al. Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study. *Mov Disord* 2006; 21(3):343-353.
- (307) Holloway RG, Shoulson I, Fahn S, Kieburtz K, Lang A, Marek K et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. *Arch Neurol* 2004; 61(7):1044-1053.
- (308) Nagatsu T, Sawada M. Molecular mechanism of the relation of monoamine oxidase B and its inhibitors to Parkinson's disease: possible implications of glial cells. *J Neural Transm Suppl* 2006;(71):53-65.

- (309) A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. *Arch Neurol* 2004; 61(4):561-566.
- (310) Esselink RA, de Bie RM, de Haan RJ, Lenders MW, Nijssen PC, Staal MJ et al. Unilateral pallidotomy versus bilateral subthalamic nucleus stimulation in PD: a randomized trial. *Neurology* 2004; 62(2):201-207.
- (311) Schuurman PR, Bosch DA, Bossuyt PM, Bonsel GJ, van Someren EJ, de Bie RM et al. A comparison of continuous thalamic stimulation and thalamotomy for suppression of severe tremor. *N Engl J Med* 2000; 342(7):461-468.
- (312) McIntyre CC, Savasta M, Kerkerian-Le GL, Vitek JL. Uncovering the mechanism(s) of action of deep brain stimulation: activation, inhibition, or both. *Clin Neurophysiol* 2004; 115(6):1239-1248.
- (313) Deuschl G, Schade-Brittinger C, Krack P, Volkmann J, Schafer H, Botzel K et al. A randomized trial of deep-brain stimulation for Parkinson's disease. *N Engl J Med* 2006; 355(9):896-908.
- (314) Schupbach WM, Maltete D, Houeto JL, du Montcel ST, Mallet L, Welter ML et al. Neurosurgery at an earlier stage of Parkinson disease: a randomized, controlled trial. *Neurology* 2007; 68(4):267-271.
- (315) Funkiewiez A, Ardouin C, Caputo E, Krack P, Fraix V, Klinger H et al. Long term effects of bilateral subthalamic nucleus stimulation on cognitive function, mood, and behaviour in Parkinson's disease. *J Neurol Neurosurg Psychiatry* 2004; 75(6):834-839.
- (316) Herzog J, Volkmann J, Krack P, Kopper F, Potter M, Lorenz D et al. Two-year follow-up of subthalamic deep brain stimulation in Parkinson's disease. *Mov Disord* 2003; 18(11):1332-1337.
- (317) Krack P, Batir A, Van BN, Chabardes S, Fraix V, Ardouin C et al. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. *N Engl J Med* 2003; 349(20):1925-1934.
- (318) Lagrange E, Krack P, Moro E, Ardouin C, Van BN, Chabardes S et al. Bilateral subthalamic nucleus stimulation improves health-related quality of life in PD. *Neurology* 2002; 59(12):1976-1978.
- (319) Rusmann H, Ghika J, Villemure JG, Robert B, Bogouslavsky J, Burkhard PR et al. Subthalamic nucleus deep brain stimulation in Parkinson disease patients over age 70 years. *Neurology* 2004; 63(10):1952-1954.
- (320) Tavella A, Bergamasco B, Bosticco E, Lanotte M, Perozzo P, Rizzone M et al. Deep brain stimulation of the subthalamic nucleus in Parkinson's disease: long-term follow-up. *Neurol Sci* 2002; 23 Suppl 2:S111-S112.
- (321) Welter ML, Houeto JL, Tezenas du MS, Mesnage V, Bonnet AM, Pillon B et al. Clinical predictive factors of subthalamic stimulation in Parkinson's disease. *Brain* 2002; 125(Pt 3):575-583.
- (322) Kleiner-Fisman G, Herzog J, Fisman DN, Tamma F, Lyons KE, Pahwa R et al. Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes. *Mov Disord* 2006; 21 Suppl 14:S290-S304.
- (323) Parsons TD, Rogers SA, Braaten AJ, Woods SP, Troster AI. Cognitive sequelae of subthalamic nucleus deep brain stimulation in Parkinson's disease: a meta-analysis. *Lancet Neurol* 2006; 5(7):578-588.
- (324) Witt K, Daniels C, Reiff J, Krack P, Volkmann J, Pinski MO et al. Neuropsychological and psychiatric changes after deep brain stimulation for Parkinson's disease: a randomised, multicentre study. *Lancet Neurol* 2008; 7(7):605-614.
- (325) Smeding HM, Speelman JD, Koning-Haanstra M, Schuurman PR, Nijssen P, van LT et al. Neuropsychological effects of bilateral STN stimulation in Parkinson disease: a controlled study. *Neurology* 2006; 66(12):1830-1836.
- (326) Volkmann J, Allert N, Voges J, Weiss PH, Freund HJ, Sturm V. Safety and efficacy of pallidal or subthalamic nucleus stimulation in advanced PD. *Neurology* 2001; 56(4):548-551.
- (327) Volkmann J ANVJWPFH-JSV. Safety and efficacy of pallidal or subthalamic nucleus stimulation in advanced Parkinson's disease. *Neurology* 2001; 56:548-551.
- (328) Lohr TJ, Burgunder JM, Pohle T, Weber S, Sommerhalder R, Krauss JK. Long-term pallidal deep brain stimulation in patients with advanced Parkinson disease: 1-year follow-up study. *J Neurosurg* 2002; 96(5):844-853.
- (329) Anderson VC, Burchiel KJ, Hogarth P, Favre J, Hammerstad JP. Pallidal vs subthalamic nucleus deep brain stimulation in Parkinson disease. *Arch Neurol* 2005; 62(4):554-560.

- (330) Fields JA, Troster AI, Wilkinson SB, Pahwa R, Koller WC. Cognitive outcome following staged bilateral pallidal stimulation for the treatment of Parkinson's disease. *Clin Neurol Neurosurg* 1999; 101(3):182-188.
- (331) Ardouin C, Pillon B, Peiffer E, Bejjani P, Limousin P, Damier P et al. Bilateral subthalamic or pallidal stimulation for Parkinson's disease affects neither memory nor executive functions: a consecutive series of 62 patients. *Ann Neurol* 1999; 46(2):217-223.
- (332) Pillon B, Ardouin C, Damier P, Krack P, Houeto JL, Klinger H et al. Neuropsychological changes between "off" and "on" STN or GPi stimulation in Parkinson's disease. *Neurology* 2000; 55(3):411-418.
- (333) Rodriguez-Oroz MC, Obeso JA, Lang AE, Houeto JL, Pollak P, Rehncrona S et al. Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up. *Brain* 2005; 128(Pt 10):2240-2249.
- (334) Volkmann J, Allert N, Voges J, Sturm V, Schnitzler A, Freund HJ. Long-term results of bilateral pallidal stimulation in Parkinson's disease. *Ann Neurol* 2004; 55(6):871-875.
- (335) Benabid AL, Pollak P, Seigneuret E, Hoffmann D, Gay E, Perret J. Chronic VIM thalamic stimulation in Parkinson's disease, essential tremor and extra-pyramidal dyskinesias. *Acta Neurochir Suppl (Wien)* 1993; 58:39-44.
- (336) Krauss JK, Simpson RK, Jr., Ondo WG, Pohle T, Burgunder JM, Jankovic J. Concepts and methods in chronic thalamic stimulation for treatment of tremor: technique and application. *Neurosurgery* 2001; 48(3):535-541.
- (337) Ondo W, Dat VK, Almaguer M, Jankovic J, Simpson RK. Thalamic deep brain stimulation: effects on the nontarget limbs. *Mov Disord* 2001; 16(6):1137-1142.
- (338) Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease. *N Engl J Med* 2001; 345(13):956-963.
- (339) Krause M, Fogel W, Heck A, Hacke W, Bonsanto M, Trenkwalder C et al. Deep brain stimulation for the treatment of Parkinson's disease: subthalamic nucleus versus globus pallidus internus. *J Neurol Neurosurg Psychiatry* 2001; 70(4):464-470.
- (340) Krack P, Pollak P, Limousin P, Hoffmann D, Xie J, Benazzouz A et al. Subthalamic nucleus or internal pallidal stimulation in young onset Parkinson's disease. *Brain* 1998; 121 (Pt 3):451-457.
- (341) Nederlandse Vereniging Neuroverpleegkundigen en Verzorgenden. Richtlijn verpleging en verzorging van mensen met Parkinson. Utrecht: V&VN; 2001.
- (342) Reynolds H, Wilson-Barnett J, Richardson G. Evaluation of the role of the Parkinson's disease nurse specialist. *Int J Nurs Stud* 2000; 37(4):337-349.
- (343) Jahanshahi M, Brown RG, Whitehouse C, Quinn N, Marsden CD. Contact with a nurse practitioner: A short-term evaluation study in Parkinson's disease and dystonia. *Behavioural Neurology* 1994; 7:189-196.
- (344) Het beroepsprofiel van de fysiotherapeut. www.fysionet.nl [2008
- (345) Keus SHJ, Hendriks HJM, Bloem BR, Bredero-Cohen AB, de Goede CJT, van Haaren M et al. KNGF-richtlijn ziekte van Parkinson. *Ned Tijdschr Fysiother* 2004; 114 (Suppl.)(3 www.kngf.nl).
- (346) Keus SHJ, Bredero-Cohen AB, Bloem BR, Hendriks HJM, de Goede CJT, van Haaren M et al. Richtlijn Cesar & de Ziekte van Parkinson. Utrecht: Vereniging van oefentherapeuten Cesar & Mensendieck (www.vvocm.nl); 2005.
- (347) Keus SHJ, Bredero-Cohen AB, Bloem BR, Hendriks HJM, de Goede CJT, van Haaren M et al. Richtlijn Oefentherapie Mensendieck bij patiënten met de ziekte van Parkinson. Amersfoort / Utrecht: Nederlands Paramedisch Instituut / Vereniging van oefentherapeuten Cesar & Mensendieck (www.vvocm.nl); 2005.
- (348) Goodwin VA, Richards SH, Taylor RS, Taylor AH, Campbell JL. The effectiveness of exercise interventions for people with Parkinson's disease: A systematic review and meta-analysis. *Mov Disord* 2008; 23:-631.
- (349) Keus SH, Bloem BR, Hendriks EJ, Bredero-Cohen AB, Munneke M. Evidence-based analysis of physical therapy in Parkinson's disease with recommendations for practice and research. *Mov Disord* 2007; 22(4):451-460.
- (350) Kwakkel G, de GCJ, Van WEE. Impact of physical therapy for Parkinson's disease: A critical review of the literature. *Parkinsonism Relat Disord* 2007; 13:S478-S487.
- (351) Lim I, van WE, de GC, Deutekom M, Nieuwboer A, Willems A et al. Effects of external rhythmical cueing on gait in patients with Parkinson's disease: a systematic review. *Clin Rehabil* 2005; 19(7):695-713.

- (352) Smidt N, de Vet HC, Bouter LM, Dekker J, Arendzen JH, de Bie RA et al. Effectiveness of exercise therapy: a best-evidence summary of systematic reviews. *Aust J Physiother* 2005; 51(2):71-85.
- (353) Taylor NF, Dodd KJ, Shields N, Bruder A. Therapeutic exercise in physiotherapy practice is beneficial: a summary of systematic reviews 2002-2005. *Aust J Physiother* 2007; 53(1):7-16.
- (354) Sturkenboom IHWM, Thijssen MCE, Gons-van de Elsacker JJ, Jansen IJH, Maasdam A, Schulten M et al. *Ergotherapie bij de ziekte van Parkinson, een richtlijn van Ergotherapie Nederland*. Utrecht / Den Haag: Ergotherapie Nederland / Uitgeverij Lemma; 2008.
- (355) Dixon L, Duncan D, Johnson P, Kirkby L, O'Connell H, Taylor H et al. Occupational therapy for patients with Parkinson's disease. *Cochrane Database Syst Rev* 2007;(3):CD002813.
- (356) Kalf H, de Swart B, Bonnier-Baars M, Kanters J, Kocken J, Munneke M. *Logopedie bij de ziekte van Parkinson - Een richtlijn van de Nederlandse Vereniging voor Logopedie en Foniatrie*. Den Haag: Lemma/Boom uitgevers; 2008.
- (357) Deane KH, Whurr R, Playford ED, Ben-Shlomo Y, Clarke CE. A comparison of speech and language therapy techniques for dysarthria in Parkinson's disease. *Cochrane Database Syst Rev* 2001;(2):CD002814.
- (358) de Swart BJ, Willemse SC, Maassen BA, Horstink MW. Improvement of voicing in patients with Parkinson's disease by speech therapy. *Neurology* 2003; 60(3):498-500.
- (359) Cubo E, Rojo A, Ramos S, Quintana S, Gonzalez M, Kompolti K et al. The importance of educational and psychological factors in Parkinson's disease quality of life. *Eur J Neurol* 2002; 9(6):589-593.
- (360) Martinez-Martin P, Benito-León J, Alonso F, Catalan MJ, Pondal M, Zamarbide I et al. Quality of life of caregivers in Parkinson's disease. *Qual Life Res* 2005; 14(2):463-472.
- (361) Mittelman M. Taking care of the caregivers. *Curr Opin Psychiatry* 2005; 18(6):633-639.
- (362) Simons G, Thompson SB, Smith Pasqualini MC. An innovative education programme for people with Parkinson's disease and their carers. *Parkinsonism Relat Disord* 2006; 12(8):478-485.
- (363) Spliethoff-Kamminga NGA. *Patient Educatie Programma Parkinson*. Amsterdam: Harcourt Assessment B.V.; 2006.
- (364) Macht M, Gerlich C, Ellgring H, Schradi M, Rusinol AB, Crespo M et al. Patient education in Parkinson's disease: Formative evaluation of a standardized programme in seven European countries. *Patient Educ Couns* 2007; 65(2):245-252.
- (365) Wade DT, Gage H, Owen C, Trend P, Grossmith C, Kaye J. Multidisciplinary rehabilitation for people with Parkinson's disease: a randomised controlled study. *J Neurol Neurosurg Psychiatry* 2003; 74(2):158-162.
- (366) van der Marck M, Bloem BR, Munneke M. Multidisciplinaire behandeling van de ziekte van Parkinson. *Tijdschr Neurol Neurochirurg* 2006; 107:66-68.
- (367) Happe S, Ludemann P, Berger K. The association between disease severity and sleep-related problems in patients with Parkinson's disease. *Neuropsychobiology* 2002; 46(2):90-96.
- (368) Verbaan D, van Rooden SM, Visser M, Marinus J, van Hilten JJ. Nighttime sleep problems and daytime sleepiness in Parkinson's disease. *Mov Disord* 2008; 23(1):35-41.
- (369) Bloem BR, Grimbergen YA, Cramer M, Willemsen M, Zwiderman AH. Prospective assessment of falls in Parkinson's disease. *J Neurol* 2001; 248(11):950-958.
- (370) Wood BH, Bilclough JA, Bowron A, Walker RW. Incidence and prediction of falls in Parkinson's disease: a prospective multidisciplinary study. *J Neurol Neurosurg Psychiatry* 2002; 72(6):721-725.
- (371) Ashburn A, Stack E, Pickering RM, Ward CD. A community-dwelling sample of people with Parkinson's disease: characteristics of fallers and non-fallers. *Age Ageing* 2001; 30(1):47-52.
- (372) Wenning GK, Ebersbach G, Verny M, Chaudhuri KR, Jellinger K, McKee A et al. Progression of falls in postmortem-confirmed parkinsonian disorders. *Mov Disord* 1999; 14(6):947-950.
- (373) Schaafsma JD, Giladi N, Balash Y, Bartels AL, Gurevich T, Hausdorff JM. Gait dynamics in Parkinson's disease: relationship to Parkinsonian features, falls and response to levodopa. *J Neurol Sci* 2003; 212(1-2):47-53.
- (374) Nederlandse Vereniging voor Klinische Geriatrie. *Richtlijn preventie van valincidenten bij ouderen*. Utrecht / Alphen aan de Rijn: CBO / Van Zuiden Communications (www.cbo.nl); 2004.

- (375) Stuurgroep Ondervoeding. Richtlijn Ondervoeding. Screening en behandeling van ondervoeding. www.stuurgroepondervoeding.nl 2009.
- (376) Abbott RA, Cox M, Markus H, Tomkins A. Diet, body size and micronutrient status in Parkinson's disease. *Eur J Clin Nutr* 1992; 46(12):879-884.
- (377) Chen H, Zhang SM, Hernan MA, Willett WC, Ascherio A. Weight loss in Parkinson's disease. *Ann Neurol* 2003; 53(5):676-679.
- (378) Kempster PA, Wahlqvist ML. Dietary factors in the management of Parkinson's disease. *Nutr Rev* 1994; 52(2 Pt 1):51-58.
- (379) Gazewood JD, Mehr DR. Diagnosis and management of weight loss in the elderly. *J Fam Pract* 1998; 47(1):19-25.
- (380) Nilsson H, Ekberg O, Olsson R, Hindfelt B. Quantitative assessment of oral and pharyngeal function in Parkinson's disease. *Dysphagia* 1996; 11(2):144-150.
- (381) Johnston BT, Li Q, Castell JA, Castell DO. Swallowing and esophageal function in Parkinson's disease. *Am J Gastroenterol* 1995; 90(10):1741-1746.
- (382) Morgante L, Salemi G, Meneghini F, Di Rosa AE, Epifanio A, Grigoletto F et al. Parkinson disease survival: a population-based study. *Arch Neurol* 2000; 57(4):507-512.
- (383) Logemann JA. Dysphagia in movement disorders. *Adv Neurol* 1988; 49:307-316.
- (384) Pfeiffer RF. Gastrointestinal dysfunction in Parkinson's disease. *Clin Neurosci* 1998; 5(2):136-146.
- (385) Stocchi F, Carbone A, Inghilleri M, Monge A, Ruggieri S, Berardelli A et al. Urodynamic and neurophysiological evaluation in Parkinson's disease and multiple system atrophy. *J Neurol Neurosurg Psychiatry* 1997; 62(5):507-511.
- (386) Erdem N, Chu FM. Management of overactive bladder and urge urinary incontinence in the elderly patient. *Am J Med* 2006; 119(3 Suppl 1):29-36.
- (387) Bolle G. Ziekte van Parkinson. In: Gianotten WL, Meihuizen-de Regt MJ, van Son-Schoones N, editors. *Seksualiteit bij ziekte en lichamelijke beperking*. Assen: Koninklijke Van Gorcum; 2008. 355-361.
- (388) Jacobs H, Viergge A, Viergge P. Sexuality in young patients with Parkinson's disease: a population based comparison with healthy controls. *J Neurol Neurosurg Psychiatry* 2000; 69(4):550-552.
- (389) Bronner G, Royter V, Korczyn AD, Giladi N. Sexual dysfunction in Parkinson's disease. *J Sex Marital Ther* 2004; 30(2):95-105.
- (390) Singer C, Weiner WJ, Sanchez-Ramos JR. Autonomic dysfunction in men with Parkinson's disease. *Eur Neurol* 1992; 32(3):134-140.
- (391) Macht M, Schwarz R, Ellgring H. Patterns of psychological problems in Parkinson's disease. *Acta Neurol Scand* 2005; 111(2):95-101.
- (392) Nappi RE, Detaddei S, Veneroni F, Fignoni A, Farina C, Ferdeghini F et al. Sexual disorders in Parkinson's disease. *Funct Neurol* 2001; 16(3):283-288.
- (393) Raffaele R, Vecchio I, Giammusso B, Morgia G, Brunetto MB, Rampello L. Efficacy and safety of fixed-dose oral sildenafil in the treatment of sexual dysfunction in depressed patients with idiopathic Parkinson's disease. *Eur Urol* 2002; 41(4):382-386.
- (394) Allcock LM, Ulliyart K, Kenny RA, Burn DJ. Frequency of orthostatic hypotension in a community based cohort of patients with Parkinson's disease. *J Neurol Neurosurg Psychiatry* 2004; 75(10):1470-1471.
- (395) van Dijk JG, Haan J, Zwinderman K, Kremer B, van Hilten BJ, Roos RA. Autonomic nervous system dysfunction in Parkinson's disease: relationships with age, medication, duration, and severity. *J Neurol Neurosurg Psychiatry* 1993; 56(10):1090-1095.
- (396) van Dijk JG. Explaining syncope: faints need not confuse. *Europace* 2005; 7(4):392-395.
- (397) Wieling W, van Lieshout JJ, van Leeuwen AM. Physical manoeuvres that reduce postural hypotension in autonomic failure. *Clin Auton Res* 1993; 3(1):57-65.
- (398) Swinn L, Schrag A, Viswanathan R, Bloem BR, Lees A, Quinn N. Sweating dysfunction in Parkinson's disease. *Mov Disord* 2003; 18(12):1459-1463.
- (399) EADIE MJ, TYRER JH. ALIMENTARY DISORDER IN PARKINSONISM. *Australas Ann Med* 1965; 14:13-22.
- (400) Edwards LL, Pfeiffer RF, Quigley EM, Hofman R, Balluff M. Gastrointestinal symptoms in Parkinson's disease. *Mov Disord* 1991; 6(2):151-156.
- (401) Scott B, Borgman A, Engler H, Johnels B, Aquilonius SM. Gender differences in Parkinson's disease symptom profile. *Acta Neurol Scand* 2000; 102(1):37-43.
- (402) Proulx M, de Courval FP, Wiseman MA, Panisset M. Salivary production in Parkinson's disease. *Mov Disord* 2005; 20(2):204-207.

- (403) Tumilasci OR, Cersosimo MG, Belforte JE, Micheli FE, Benarroch EE, Pazo JH. Quantitative study of salivary secretion in Parkinson's disease. *Mov Disord* 2006; 21(5):660-667.
- (404) Chou KL, Evatt M, Hinson V, Kompoliti K. Sialorrhea in Parkinson's disease: a review. *Mov Disord* 2007; 22(16):2306-2313.
- (405) Hyson HC, Johnson AM, Jog MS. Sublingual atropine for sialorrhea secondary to parkinsonism: a pilot study. *Mov Disord* 2002; 17(6):1318-1320.
- (406) Postma AG, Heesters M, van LT. Radiotherapy to the salivary glands as treatment of sialorrhea in patients with parkinsonism. *Mov Disord* 2007; 22(16):2430-2435.
- (407) Ford B. Pain in Parkinson's disease. *Clin Neurosci* 1998; 5(2):63-72.
- (408) Banks P, Lawrence M. The Disability Discrimination Act, a necessary, but not sufficient safeguard for people with progressive conditions in the workplace? The experiences of younger people with Parkinson's disease. *Disabil Rehabil* 2006; 28(1):13-24.
- (409) Schrag A, Banks P. Time of loss of employment in Parkinson's disease. *Mov Disord* 2006; 21(11):1839-1843.
- (410) Nijkraak MJ, Bloem BR, Keus SH, Mulleners W. Quality of allied health care in Parkinson's disease. *Mov Disord* 2006; 21:S131.
- (411) Kashihara K. Weight loss in Parkinson's disease. *J Neurol* 2006; 253 Suppl 7:VII38-VII41.
- (412) Ashburn A, Stack E, Pickering RM, Ward CD. Predicting fallers in a community-based sample of people with Parkinson's disease. *Gerontology* 2001; 47(5):277-281.
- (413) Michalowska M, Fiszer U, Krygowska-Wajs A, Owczarek K. Falls in Parkinson's disease. Causes and impact on patients' quality of life. *Funct Neurol* 2005; 20(4):163-168.
- (414) Schrag A, Hovris A, Morley D, Quinn N, Jahanshahi M. Caregiver-burden in Parkinson's disease is closely associated with psychiatric symptoms, falls, and disability. *Parkinsonism & Related Disorders* 2006; 12(1):35-41.
- (415) Goetz CG, Koller WC, Poewe W, Rascol O, Sampaio C, Lozano A et al. Treatment of depression in idiopathic Parkinson's disease. *Mov Disord* 2002; 17((Suppl.4)):S112-S119.
- (416) Keus SHJ, Bloem BR, Verbaan D, de Jonge P, Hofman AM, van Hilten JJ et al. Physiotherapy in Parkinson's disease: utilisation and patient satisfaction. *J Neurol* 2004; 251(6):680-687.